China's Clover to complete COVID-19 booster vaccine development in 2022

Clover Biopharmaceuticals

15/02/2022 05:15

** Shares of China's vaccine developer Clover
Biopharmaceuticals Ltd  2197.HK  fall 7.6% to HK$9.81, the
lowest since Nov. 12 
    ** Stock set for the biggest daily percentage decline since
Dec. 20, and on track for four consecutive sessions of decline
    ** Sichuan, China-based co says it plans to complete
development of its COVID-19 vaccine candidate this year to
potentially enable its use as a universal booster dose
 urn:newsml:reuters.com:*:nFWN2UP0TI
    ** Co expects to complete regulatory submissions by mid-2022
for the China's National Medical Products Administration and by
the third quarter of 2022 for the World Health Organization
(WHO) and the European Medicines Agency 
    ** Says it received WHO's feedback in December related to
its Changxing facility, following which co has taken certain
steps; expects facility to be ready for additional good
manufacturing practices inspections by second quarter of 2022
    ** Says it is pursuing a multi-prong strategy to evaluate
and tackle the Omicron variant 
    ** Hang Seng Commerce & Industry Index  .HSNC  edges down
0.04%, while healthcare index  .HSCIH  rises 4%
    ** Hang Seng China Enterprises Index  .HSCE  slips 1%, and
the benchmark Hang Seng Index  .HSI  eases 0.7%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))